NEW YORK (Reuters Health) – In high vascular risk patients, addition of clopidogrel to treatment with acetylsalicylic acid does not help minimize untoward events, researchers report in the…
NEW YORK (Reuters Health) – Despite numerous advances in treatment, evidence-based outpatient therapy for congestive heart failure (CHF) has not improved since 2002, researchers report in the August…
NEW YORK (Reuters Health) – Patients with an acute coronary syndrome referred for invasive treatment have similar outcomes whether they are given double-dose or standard-dose clopidogrel plus higher-dose…
NEW YORK (Reuters Health) – By lowering heart rate, the selective sinoatrial current inhibitor ivabradine improves outcomes in patients with chronic heart failure and an elevated heart rate,…
NEW YORK (Reuters Health) – Patients undergoing percutaneous coronary intervention for acute coronary syndrome initially treated with the synthetic factor Xa inhibitor fondaparinux do not have significantly lower…
NEW YORK (Reuters Health) – While clopidogrel’s effectiveness in the treatment of acute coronary syndromes is affected by a patient’s genotype, the efficacy of ticagrelor is not. Therefore,…
NEW YORK (Reuters Health) – Elderly patients with heart failure have an increasing mortality risk as their dose of furosemide increases, after taking into account multiple confounders, a…
NEW YORK (Reuters Health) – Coronary heart disease that continues to progress to serious events in patients whose LDL levels have been brought down adequately — called “residual…
NEW YORK (Reuters Health) – Recommendations issued by the European Society of Cardiology emphasize the need to consider the clinical context in interpreting cardiac troponin readings in acute…